French pharmas' revenue down 16% since 2010French pharmas' revenue has fallen 16% since 2010 because of price reductions, reported Les Echos (p19) and Le Figaro (p26) on Thursday.
Dassault Systèmes buys MedidataDassault Systèmes is buying U.S. digital life sciences platform specialist Medidata for $5.8 billion, Le Figaro (p27), Les Echos (p21 and 32), and La Croix (p10) reported on Thursday (APMHE 63308).
Paul Hudson appointed Sanofi CEOPaul Hudson has been appointed the new chief executive of Sanofi, Les Echos (p20) announced on Tuesday (APMHE 63257).
Insys files for bankruptcyU.S. firm Insys has filed for bankruptcy, Libération (p11) reported on Tuesday (APMHE 63290).
Report on Levothyrox by the France's drugs' regulator ANSMA report from France's drugs' regulator ANSM concluded that the new version of Merck KGaA's Levothyrox (levothyroxine) does not lead to serious health issues, reports 20 minutes on Friday.
French homeopathy specialist Boiron counter attacksFrance's homeopathy specialist Boiron has counter attacked to defend the reimbursement of homeopathy to France's healthcare technology assessment body HAS, reported La Croix (p8) on Wednesday.
AmyPore develops new therapeutic pathway for Alzheimer's diseaseFrench biotech AmyPore has developed a new therapeutic pathway for Alzheimer's disease, linked to a chimeric peptide, Les Echos (p30) reported on Tuesday.
Yukin Therapeutics raises €3.3 millionFrench start-up Yukin Therapeutics, specialising in the development of new molecules for cancer treatment, has raised €3.3 million, Les Echos (p25) reported on Thursday.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.